HOWL - Werewolf Therapeutics Inc
IEX Last Trade
2.14
-0.080 -3.738%
Share volume: 150,977
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$2.22
-0.08
-3.60%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-11 | 2022-11-10 | 2023-03-23 | 2023-05-11 | 2023-08-10 | 2023-11-14 | 2024-03-07 | 2024-05-03 | |
| Total revenue | 4.148 M | 4.970 M | 7.283 M | 4.464 M | 8.081 M | 5.897 M | 1.501 M | 742.000 K | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 4.148 M | 4.970 M | 7.283 M | 4.464 M | 8.081 M | 5.897 M | 1.501 M | 742.000 K | |
| 19.82% | 46.54% | -38.71% | 81.03% | -27.03% | -74.55% | -50.57% | |||
| Operating expenses | 19.120 M | 17.509 M | 20.462 M | 16.687 M | 14.148 M | 15.148 M | 14.463 M | 17.904 M | |
| Selling general and admin | 5.233 M | 4.439 M | 4.603 M | 4.981 M | 4.565 M | 4.310 M | 4.814 M | 4.996 M | |
| Research and development | 13.887 M | 13.070 M | 15.859 M | 11.706 M | 9.583 M | 10.838 M | 9.649 M | 12.908 M | |
| Total expenses | 19.120 M | 17.509 M | 20.462 M | 16.687 M | 14.148 M | 15.148 M | 14.463 M | 17.904 M | |
| -8.43% | 16.87% | -18.45% | -15.22% | 7.07% | -4.52% | 23.79% | |||
| Operating income | -14.972 M | -12.539 M | -13.179 M | -12.223 M | -6.067 M | -9.251 M | -12.962 M | -17.162 M | |
| Ebit | -14.972 M | -12.539 M | -13.179 M | -12.223 M | -6.067 M | -9.251 M | -12.962 M | -17.162 M | |
| Pretax income | -14.594 M | -11.943 M | -11.930 M | -11.982 M | -5.098 M | -8.285 M | -12.003 M | -16.193 M | |
| -18.16% | -0.11% | 0.44% | -57.45% | 62.51% | 44.88% | 34.91% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | -14.594 M | -11.943 M | -11.930 M | -11.982 M | -5.098 M | -8.285 M | -12.003 M | -16.193 M | |
| 18.16% | 0.11% | -0.44% | 57.45% | -62.51% | -44.88% | -34.91% | |||
| Net income | -14.594 M | -11.943 M | -11.930 M | -11.982 M | -5.098 M | -8.285 M | -12.003 M | -16.193 M | |
| 18.16% | 0.11% | -0.44% | 57.45% | -62.51% | -44.88% | -34.91% |